Final analysis of efficacy: Covaxin 65.2% effective against Delta variant

Hyderabad: Bharat Biotech’s Covaxin has demonstrated 77.8 per cent effectiveness against symptomatic COVID-19 and 65.2 per cent protection against the new Delta variant.

The company on Saturday said it concluded the final analysis of Covaxin efficacy from Phase 3 trials.

The efficacy analysis demonstrates Covaxin to be 93.4 per cent effective against severe symptomatic COVID-19 cases while safety analysis shows adverse events reported were similar to placebo, with 12 per cent of subjects experiencing commonly known side effects and less than 0.5 per cent feeling serious adverse events.